Vamorolone Patent Expiration

Vamorolone is Used for treating Duchenne Muscular Dystrophy. It was first introduced by Catalyst Pharmaceuticals Inc in its drug Agamree on Oct 26, 2023.


Vamorolone Patents

Given below is the list of patents protecting Vamorolone, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Agamree US10857161 Non-hormonal steroid modulators of NF-kB for treatment of disease May 28, 2029 Catalyst Pharms
Agamree US11382922 Aqueous oral pharmaceutical suspension compositions Jul 16, 2040 Catalyst Pharms
Agamree US11471471 Aqueous oral pharmaceutical suspension compositions Mar 17, 2040 Catalyst Pharms
Agamree US11690853 Non-hormonal steroid modulators of NF-κβ for treatment of disease Mar 07, 2033 Catalyst Pharms
Agamree US11833159 Non-hormonal steroid modulators of NF-kB for treatment of disease May 28, 2029 Catalyst Pharms
Agamree US8334279 Non-hormonal steroid modulators of NF-κB for treatment of disease May 28, 2029 Catalyst Pharms


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳